Cutler Group’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Cutler Group’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-10	Closed	-$7K	–	7267
2017 Q1	$7K	Sell	10 -50	-83%	-$23.2K	﹤0.01%	4449
2016 Q4	$27K	Sell	60 -13	-18%	-$13.7K	﹤0.01%	3167
2016 Q3	$11K	Buy	73 +3	+4%	+$3.24K	﹤0.01%	4145
2016 Q2	$36K	Buy	70 +9	+15%	+$11.3K	﹤0.01%	2714
2016 Q1	$41K	Buy	61 +16	+36%	+$22.8K	﹤0.01%	2539
2015 Q4	$14K	Buy	+45	New	+$69.1K	﹤0.01%	3800

Other funds holding NBSE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GBA

Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Cutler Group's NBSE Position: Q2 2018 in Review

Cutler Group held its NeuBase Therapeutics, Inc. Common Stock (NBSE) position steady in Q2 2018 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5069.

Cutler Group first reported a position in NBSE in Q4 2015 and has held it in 5 quarters since. The position peaked at $68K in Q1 2016. 33 funds tracked by Wall St. Rank hold NBSE as of Q2 2018.

Cutler Group held 0 shares of NeuBase Therapeutics, Inc. Common Stock worth $0 as of Q2 2018.
Cutler Group left its NeuBase Therapeutics, Inc. Common Stock share count unchanged in Q2 2018.
NeuBase Therapeutics, Inc. Common Stock made up ﹤0.01% of Cutler Group's portfolio in Q2 2018, its #5069 holding.
Cutler Group first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q4 2015 and has held it in 5 quarters since.
Cutler Group's NeuBase Therapeutics, Inc. Common Stock position peaked at $68K in Q1 2016.
33 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2018.

Based on Cutler Group's 13F filing for Q2 2018, filed 10 Aug 2018.